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from first day of chemotherapy to death of any cause) were 
evaluated. 
Results: A total of 43 patients were included. The median 
follow-up was 45 months (range 6-105 months). Five year 
DFS, PFS and OS were 90%, 76% and 86% respectively. On 
post-chemotherapy PET, CR was seen in 35 patients (81%), 
partial response in three patients (7%) and progression in five 
patients (12%).  
Of the patients with CR, three patients (9%) relapsed, all in 
initial sites of disease with one patient also relapsing in new 
sites. Three of four patients with bulky disease (defined as a 
single nodal mass of 10cm or greater) received consolidative 
RT and none of these patients relapsed. Five year OS for 
patients with PET CR was 94%. Two patients died, one from 
progressive disease and one from bleomycin-related lung 
toxicity. 
Conclusions: Advanced stage HL with PET CR following ABVD 
chemotherapy is associated with an excellent prognosis. 
Relapses were low and occurred in both initial and new sites. 
The use of consolidative RT for bulky disease provided good 
disease control, with no relapses observed.  
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Purpose/Objective: Stereotactic radiosurgery (SRS) is an 
alternative to post-operative whole brain radiation therapy 
(WBRT) following resection of brain metastases. At our 
institution, CyberKnife (CK) is generally used for local 
treatment of larger cavities. In this study, we aimed to 
evaluate patterns of failure with this approach and assess 
whether size of lesion correlated with local failure. 
Materials and Methods: We retrospectively reviewed 30 
patients treated with CK to 33 lesions between 2011-2014. 
Both the cavity resection volume (GTV) and CK treatment 
volume (PTV) were analyzed on treatment planning MRI for 
all cases. Patterns of intracranial control were analyzed in 26 
patients with post-treatment imaging. Survival was estimated 
by the Kaplan Meier method and prognostic factors for local 
and distant control were examined with Fisher’s exact test. 
Results: The most common histologies were lung (42%), 
breast (21%), and melanoma (15%). The cohort was evenly 
split by gender and generally RPA I (33%) and RPA II (57%). 
Median preoperative diameter was 3.3cm and 57% of patients 
underwent gross total resection. Median cavity volume was 
17.5cm3 (range 2.4-69.8 cm3) and median treatment volume 
was 25.11cm3 (range 4.7-90.9cm3). Treatments were 
delivered to a median 30 Gy in 5 fractions to the 75% isodose 
line. Synchronous metastases were treated at the time of CK 
in 33% of cases. The median clinical follow up for the 13 
living patients was 16.9 months (range 4.4-35.2) and for the 
entire cohort of 30 patients was 9.5 months (range 1.0-34.3). 
Local failure developed in 7 treated cavities (23%) and 
median time to local failure was not reached. Patients with 
lung primaries were found to fail locally in five of twelve 
cases (42%) compared to two of 17 (12%) non lung histologies 
(p=0.092). Evaluation of both cavity volume and CK 
treatment volume at a variety of cut-off points showed no 
association with local failure and size (p>0.61 and 0.64, 
respectively). Distant brain failure occurred in 20 cases (63%) 
at a median of 4.6 months. Distant failure developed in eight 
of nine patients with synchronous metastases (89%) compared 
to 11 of 20 without synchronous metastases (56%) (p=0.107). 
Salvage therapies included WBRT (23%) performed at a 
median of 5.1 months from treatment and additional SRS 
(40%) at a median of 4.9 months from treatment. 
Leptomeningeal carcinomatosis developed in 12 cases (40%). 
Patients survived a median of 10.1 months from the time of 
treatment. 
Conclusions: This study suggests that large resection cavities 
are likely to achieve equivalent local control as smaller 
resection beds using adjuvant CK strategy. However, patients 
with lung primaries appear more likely to fail within this 
cohort. Most patients do develop intracranial failure which 
was correlated with synchronous metastases at the time of 
CK. The majority of patients with large cavity volumes were 
spared or delayed WBRT with the use of local CK therapy.  
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Purpose/Objective: The most common site of relapse in 
muscoloskeletal sarcomas is lung. Metastasectomy is 
considered the standard of care in these patients (pts). In 
those unfit for surgery SBRT might represent however an 
alternative approach. The purpose of this study is to evaluate 
local control and toxicity of SBRT in a group of pts treated for 
lung metastases (LM) from bone and soft tissue sarcomas. 
Materials and Methods: From October 2010 to July 2014, 24 
pts with LM from sarcomas not amenable to surgery were 
treated with daily cone beam CT guided SBRT. 22 of them 
had already been submitted at least once to thoracic surgery 
procedures, and 16 pts had been treated with several lines of 
chemotherapy. In 50% of pts the primary tumor was a soft 
tissue sarcoma and in 50% a bone sarcoma (Ewing sarcoma: 5 
pts; osteosarcoma: 3 pts; chondrosarcoma: 4 pts). 21% of pts 
had LM at diagnosis whereas 79% developed LM at a mean of 
39,9 months after initial diagnosis. 71 lesions were treated 
with SBRT. All patients underwent computed tomography 
simulation. Active breath control (ABC©) was employed to 
reduce internal margin in lesions located in the lower lobes. 
Dose was prescribed to 80% isodose. Administered dose 
ranged from 30 to 60 Gy in 3-8 fractions. Follow-up (fu) 
included physical examination and a chest CT scan +/- FDG 
PET/CT every 3 months after treatment. Response rates were 
